Table 1.
Summary of Patient Characteristics
| TCGA Cohort (N = 766) | Hazard Ratio | 95% CI | P | |
|---|---|---|---|---|
| Clinical and Demographics Variables | ||||
| Sex | ||||
| Female | 307 (41.8%) | — | ||
| Male | 427 (58.2%) | 1.12 | (0.92,1.38) | .262 |
| Age at diagnosis | ||||
| Mean (SD) | 49.7 (15.4) | 1.06 | (1.05, 1.07) | < .001 |
| Median | 51.0 | |||
| Q1, Q3 | 37.0, 61.0 | |||
| Range | 10.0–88.0 | |||
| Grade | ||||
| II | 181 (24.7%) | — | ||
| III | 205 (27.9%) | 2.98 | (1.84, 4.82) | < .001 |
| IV | 348 (47.4%) | 14.92 | (9.72, 22.91) | < .001 |
| WHO classification | ||||
| IDH-mutant astrocytoma | 203 (29.0%) | — | ||
| IDH-mutant GBM | 20 (2.9%) | 4.58 | (2.52, 8.34) | < .001 |
| IDH-mutant oligodendroglioma | 141 (20.1%) | 0.65 | (0.35,1.22) | .183 |
| IDH-wildtype astrocytoma | 72 (10.3%) | 5.66 | (3.52, 9.10) | < .001 |
| IDH-wildtype gbm | 264 (37.7%) | 11.90 | (8.22, 17.23) | < .001 |
| IDH status | ||||
| Mutant | 364 (52.0%) | — | ||
| Wildtype | 336 (48.0%) | 9.45 | (7.14, 12.50) | < .001 |
| ATRX status | ||||
| Mutant | 162 (21.1%) | — | ||
| Wildtype | 409 (53.4%) | 2.74 | (1.91, 3.93) | < .001 |
| 1p19q status | ||||
| Codeleted | 142 (18.5%) | — | ||
| Non-codeleted | 620 (80.9%) | 7.75 | (4.62, 13.00) | < .001 |
Abbreviations: IDH, isocitrate dehydrogenase 1 or 2 gene; ATRX, α-thalassemia, mental retardation, X-linked protein; 1p19q, deletion status of short arm of chromosome 1 and long arm of chromosome 19; GBM, glioblastoma multiforme.